In vitro activity of moxifloxacin (BAY 12-8039) against respiratory tract pathogens from six Latin-American countries

The in vitro antibacterial activity of moxifloxacin (BAY 12-8039) was evalu ated against 636 isolates of respiratory tract pathogens. The isolates were collected from July 1997 to August 1998 in the frame of a multinational La tin American study. E-test strips calibrated to read moxifloxacin MIC range s from 0.002 to 32 mug/ml were used in susceptibility testing. Weekly quali ty control tests in each laboratory ensured reproducibility. Laboratories f rom Argentina, Brazil, Chile, Colombia, Mexico and Uruguay participated. MI C90 for moxifloxacin were as follows: Streptococcus pneumoniae (304 isolate s) 0.25 mug/ml, Haemophilus influenzae (135 isolates) 0.125 mug/ml mi, Stre ptococcus pyogenes (66 isolates) 0.25 mug/ml, Moraxella catarrhalis (62 iso lates) 0.25 mug/ml and methicillin-sensitive Staphylococcus aureus (69 isol ates) 0.25 mug/ml. These results agreed with reports from other areas. Moxi floxacin showed excellent activity against respiratory pathogens from parti cipant countries. Copyright (C) 2000 S.Karger AG, Basel.